BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...

GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Note: Transaction values and stock performance are as of July 7, 2025. Key questions How does this transaction compare to the insider's historical trading patterns? This sale is larger than the ...